期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

降脂治疗新药物：PCSK9单克隆抗体 被引量：1

原文传递
导出
摘要 业已证实,他汀使血浆低密度脂蛋白胆固醇（LDL-C）水平的降低,对于冠心病一级预防和二级预防均有明确作用[1-2].胆固醇治疗试验协作组公布的他汀药物主要试验分析结果显示,LDL-C水平每下降1.0 mmol/L,主要心血管事件（包括心原性死亡、心肌梗死、冠状动脉血管重建以及缺血性卒中）的年发生率下降近20％[3],故目前的指南或共识[4-6]均建议采用积极的他汀治疗方案.
作者 关文池 蒋立新
机构地区 中国医学科学院北京协和医学院国家心血管病中心阜外心血管病医院心血管疾病国家重点实验室国家心血管疾病临床医学研究中心
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2014年第11期902-904,共3页 Chinese Journal of Cardiology
关键词 他汀药物 单克隆抗体 降脂治疗 低密度脂蛋白胆固醇 主要心血管事件 治疗试验 LDL-C 心原性死亡
分类号 R972.6 [医药卫生—药品]
  • 相关文献

参考文献30

  • 1O'Keefe JH Jr,Cordain L,Harris WH,et al.Optimal lowdensity lipoprotein is 50 to 70 mg/dl:lower is better and physiologically normal[J].J Am Coll Cardiol,2004,43:2142-2146.
  • 2Baigent C,Keech A,Keamey PM,et al.Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins[J].Lancet,2005,366:1267-1278.
  • 3Baigent C,Blackwell L,Emberson J,et al.Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials[J].Lancet,2010,376:1670-1681.
  • 4Reiner Z,Catapano AL,De Backer G,et al.ESC/EAS Guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the Emopean Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J].Eur Heart J,2011,32:1769-1818.
  • 5McPherson R,Frohlich J,Fodor G,et al.Canadian Cardiovascular Society position statement--recommendations for the diagnosis aad treatment of dyslipidemia and prevention of cardiovascular diseaseConsensus Development ConferenceCan J Cardiol,2006,22:913-927.
  • 6National Cholesterol Education Program (NCEP) expert panel on detection,evaluation,and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ).Third report of the National Cholesterol Education Program (NCEP) expert panel on detection,evaluation,and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ) final report guideline[J].Circulation,2002,106:3143-3421.
  • 7Waters DD,Brotons C,Chiang CW,et al.Lipid treatment assessment project 2:a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals[J].Circulation,2009,120:28-34.
  • 8Seidah NG,Prat A.The biology and therapeutic targeting of the proprotein convertases[J].Nat Rev Drug Discov,2012,11:367-383.
  • 9Horton JD,Cohen JC,Hobbs HH.PCSK9:a convertase that coordinates LDL catabolism[J].J Lipid Res,2009,50 Suppl:S172-S177.
  • 10肖文虎,张红,彭湘萍,刘录山,姜志胜.PCSK9结构与功能[J].中国生物化学与分子生物学报,2009,25(3):213-218. 被引量：8

二级参考文献29

  • 1Peterson A S, Fong L G, Young S G, et al. PCSK9 function and physiology[J]. J Lipid Res, 2008, 48(7):1595-1599.
  • 2Lagace T A, Curtis D E, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11) : 2995-3005.
  • 3Cunningham D, Danley D E, Geoghegan K F, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hyperoholesterolemia[ J]. Nat Struct Mol Biol, 2007,14(5) : 413-419.
  • 4Gallagher T, Gilliland G, Wang L, et al. The prosegment-subtilisin BPN' complex: crystal structure of a specific " foldase" [ J ]. Structure, 1995,3(9) :907-914.
  • 5Piper D E, Jackson S, Liu Q, et al. The crystal structure of PCSK9 : a regulator of plasma LDL-cholesterol [ J ]. Structure, 2007,15 (5) : 545-552.
  • 6Sanchez J F, Lescar J, Chazalet V, et al. Biochemical and structural analysis of Helix pomatia agglutinin. A hexameric lectin with a novel fold[J]. J Biol Chem,2006,281(29):20171-20180.
  • 7Zhang D W, Lagace T A, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation [ J]. J Biol Chem, 2007, 282 (25) : 18602-18612.
  • 8Pokier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of LDLR and its closest family members VLDLR and APOER2[J]. J Biol Chem, 2008,283(4) : 2363-2372.
  • 9Fisher T S, Lo Surdo P, Pandit S, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation[J]. J Biol Chem, 2007,282(28):20502-20512.
  • 10Hampton E N, Knuth M W, Li J, et al. The self-inhibited structure of full-length PCSK9 at 1. 9 A reveals structural homology with resistin within the C-terminal domain[J]. Proc Natl Acad Sci USA, 2007,104(37) : 14604-14609.

共引文献7

同被引文献3

引证文献1

二级引证文献5

中华心血管病杂志
2014年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部